Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
Clinical trial NCT06736717 · RECRUITING
Trial details
- NCT number
- NCT06736717
- Sponsor
- University of Kansas Medical Center
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-01
- Primary completion
- 2026-07-01
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.